Docoh
Loading...

SCND Scientific Industries

Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems and methods. Scientific Industries’ products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com.

Company profile

Ticker
SCND
Exchange
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
42217279

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

17 May 21
3 Aug 21
30 Jun 22
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jun 20 Jun 19 Jun 18 Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 627.5K 627.5K 627.5K 627.5K 627.5K 627.5K
Cash burn (monthly) 161.27K 9.32K 619.6K 292.63K 458.23K 163.07K
Cash used (since last report) 666.72K 38.55K 2.56M 1.21M 1.89M 674.16K
Cash remaining -39.22K 588.95K -1.93M -582.32K -1.27M -46.66K
Runway (months of cash) -0.2 63.2 -3.1 -2.0 -2.8 -0.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
29 Jun 21 Frampton Marcus Common Stock Buy Aquire P No No 10.73 500 5.37K 8,135
28 Jun 21 Frampton Marcus Common Stock Sell Dispose S Yes No 10.58 3,100 32.8K 64,760
29 Apr 21 Helena R Santos Common Stock Buy Aquire P No No 4.75 1,052 5K 254,670
29 Apr 21 Helena R Santos Warrants to Purchase Common Stock Common Stock Grant Aquire A No No 9.5 526 5K 255,196
29 Apr 21 John A Moore Common Stock Grant Aquire A No No 4.75 21,052 100K 271,204
29 Apr 21 John A Moore Warrants to Purchase Common Stock Common Stock Grant Aquire A No No 9.5 10,526 100K 281,730
29 Apr 21 Robert Nichols Common Stock Grant Aquire A No No 4.75 2,104 9.99K 29,189
29 Apr 21 Robert Nichols Warrants to Purchase Common Stock Common Stock Grant Aquire A No No 9.5 1,052 9.99K 30,241

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
  • Forward-Looking statements. Certain statements contained in this report are not based on historical facts, but are forward-looking statements that are based upon various assumptions about future conditions. Actual events in the future could differ materially from those described in the forward-looking information. Numerous unknown factors and future events could cause such differences, including but not limited to, product demand, market acceptance, success of marketing strategy, success of expansion efforts, impact of competition, adverse economic conditions, and other factors affecting the Company’s business that are beyond the Company’s control, which are discussed elsewhere in this report. Consequently, no forward-looking statement can be guaranteed. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company’s financial statements and the related notes included elsewhere in this report.
  • Overview.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: acquisition, added, aquila, Chairman, compensation, Concurrent, create, Europe, German, GmbH, impracticable, newly, offering, option, Plan, private, recently, registered, wholly
Removed: certification, chemical, duly, Helena, pertain, petrochemical, quarterly, registrant, section, security, thereunto, type, undersigned, varying